Capital Growth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capital Growth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-250,000	Closed	-$19.4M	–	77
2020 Q3	$19.4M	Sell	250,000 -290,000	-54%	-$20M	2.03%	22
2020 Q2	$30M	Sell	540,000 -340,000	-39%	-$14.5M	3.49%	7
2020 Q1	$26.1M	Buy	880,000 +35,000	+4%	+$1.18M	3.66%	8
2019 Q4	$30.6M	Buy	+845,000	New	+$25.9M	2.47%	18
2019 Q2	–	Sell	-205,000	Closed	-$5.42M	–	69
2019 Q1	$5.42M	Buy	205,000 +30,000	+17%	+$711K	0.33%	42
2018 Q4	$3.42M	Buy	175,000 +25,000	+17%	+$490K	0.21%	43
2018 Q3	$2.94M	Buy	+150,000	New	+$2.85M	0.15%	44
2017 Q1	–	Sell	-1,530,000	Closed	-$24.8M	–	76
2016 Q4	$24.8M	Buy	1,530,000 +530,000	+53%	+$9.61M	1.1%	33
2016 Q3	$18.1M	Buy	+1,000,000	New	+$19.5M	0.86%	35
2016 Q2	–	Sell	-330,000	Closed	-$5.47M	–	71
2016 Q1	$5.47M	Buy	330,000 +125,000	+61%	+$2.19M	0.23%	43
2015 Q4	$4.44M	Buy	+205,000	New	+$3.99M	0.15%	48

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Growth Management's HZNP Position: Q4 2020 in Review

Capital Growth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2020, closing a stake of 250,000 shares — an estimated $19.4M sold.

Capital Growth Management first reported a position in HZNP in Q4 2015 and held it in 11 quarters. The position peaked at $30.6M in Q4 2019. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

Capital Growth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2020 after selling out during the quarter.
Capital Growth Management sold 250,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $19.4M.
Capital Growth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 11 quarters.
Capital Growth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $30.6M in Q4 2019.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Capital Growth Management's 13F filing for Q4 2020, filed 12 Feb 2021.